title: Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys).
abstract: Chronic obstructive pulmonary disease (COPD) is characterized by an airways inflammation and by an enhanced generation of reactive oxygen species. The aim of our study was to assess the inflammation and the oxidative stress in airways of COPD patients with acute exacerbation of disease and in stability. Furthermore, we investigated the anti-inflammatory and antioxidant effects of 6 months treatment with carbocysteine lysine salt monohydrate (SCMC-Lys) in COPD. We studied 30 mild acute COPD, 10 mild stable COPD and 15 healthy subjects. 8-isoprostane and Interleukine-6 were measured in their breath condensate through immunoassay. Significantly higher concentrations of exhaled 8-isoprostane and Interleukine-6 were found in acute COPD patients compared to stable COPD and healthy controls (21.8+/-5.1 vs. 13.2+/-2.0 vs. 4.7+/-1.8 pg/ml and 7.4+/-0.9 vs. 5.8+/-0.2 vs. 2.7+/-0.6 pg/ml, p<0.0001). COPD patients treated with SCMC-Lys showed a marked reduction of exhaled 8-isoprostane and Interleukine-6 (8.9+/-1.5 and 4.6+/-0.8 pg/ml, p<0.0001). These findings suggest that there is an increase of 8-isoprostane and Interleukine-6 concentrations in the breath condensate of COPD patients compared to healthy controls especially during acute exacerbations of the disease. Moreover, we showed an anti-inflammatory and antioxidant effect of short-term administration of SCMC-Lys in COPD, suggesting the importance of a further placebo-controlled study that should evaluate the effects of this drug.
authors.affiliation: Institute of Respiratory Diseases, University of Medicine, Foggia, Italy. ge.carpagnano@unifg.it
authors.forename: Giovanna E
authors.initials: GE
authors.lastname: Carpagnano
authors.forename: O
authors.initials: O
authors.lastname: Resta
authors.forename: Maria P
authors.initials: MP
authors.lastname: Foschino-Barbaro
authors.forename: Antonio
authors.initials: A
authors.lastname: Spanevello
authors.forename: Antonio
authors.initials: A
authors.lastname: Stefano
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Gioia
authors.forename: Gaetano
authors.initials: G
authors.lastname: Serviddio
authors.forename: Enzo
authors.initials: E
authors.lastname: Gramiccioni
mesh_terms: D000328:Adult; D002233:Carbocysteine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism*; D045853:Exhalation; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012129:Respiratory Function Tests; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015850:Interleukin-6; C034932:carbocysteine-lysine; C075750:8-epi-prostaglandin F2alpha; D002233:Carbocysteine; D015237:Dinoprost